Ilenia Calcaterra: Beyond Bleeding Control Emicizumab and the Evolution of Joint Health in Hemophilia A
Ilenia Calcaterra, Consultant Physician in Internal Medicine and Assistant Professor at the University of Naples Federico II, shared a post on LinkedIn about a recent article she and her colleagues co-authored, published in Haemophilia, adding:
“Beyond bleeding control: what happens to joint health during emicizumab prophylaxis?
Pleased to share the results of the RESOLVE Study, now published in Haemophilia.
In this multicentre real-world study, we evaluated the longitudinal evolution of joint health in adults with severe haemophilia A after switching to emicizumab, combining clinical assessment with point-of-care ultrasound and HEAD-US.
After at least 2 years of prophylaxis, emicizumab was associated with a marked reduction in bleeding, with 76.9 percent of patients reporting zero joint bleeds.
But the most interesting finding came from the ultrasound assessment: among joints with hypertrophic synovium at baseline, 53.7 percent showed improvement or complete resolution.
At the same time, persistent synovial hypertrophy remained detectable in a relevant proportion of joints, particularly in the presence of pre-existing osteochondral damage.
As treatment efficacy continues to improve, our focus should increasingly move beyond ABR, integrating imaging-based surveillance, musculoskeletal assessment and individualized strategies aimed not only at preventing bleeding, but at preserving and whenever possible restoring joint health.
A great collaborative effort involving the haemophilia centres of Naples, Rome and Catanzaro”
Title: Changes in Hypertrophic Synovium Status in Adult Patients With Severe Hemophilia A Receiving Emicizumab Prophylaxis: The RESOLVE Study
Authors: Matteo Nicola Dario Di Minno, Erminia Baldacci, Ilenia Lorenza Calcaterra, Guido D’Errico, Cristina Santoro, Alessandra Strangio, Silvia Sorella, Marzia Leotta, Rita Carlotta Santoro
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 21, 2026, 15:35Danny Hsu: Pharma’s 2025 Blockbusters Through a Hematologist’s Lens
-
Oct 21, 2026, 15:12Yue Zhang: Flow Cytometry for Translational Immunology and Cancer Research
-
Oct 21, 2026, 14:58Radoš Stefanović: How Red Blood Cells Adapt After Exercise
-
Oct 21, 2026, 14:08Vera Ghali: The Role of Hepcidin Assays in Diagnosing Iron Disorders
-
Oct 21, 2026, 13:52Negar Asdaghi: Could Cilostazol Improve Hematoma Clearance After ICH
-
Oct 21, 2026, 10:33Karen Schreiber: Beyond Clinical Outcomes – The Voices of Women with APS
-
Oct 21, 2026, 10:11Tau Braun: Clots Through the Copper-Zinc Model
-
Oct 21, 2026, 09:55Cristina Figueroa Villalba: Celebrating Excellence in Transfusion Medicine
-
Oct 21, 2026, 09:43Ahmad Gharehbaghian: How Can Blood Supplies Be Sustained During a Crisis?